8-K: LivaNova Reports Strong 2023 Results and Announces New CEO

LivaNova PLC reported a 12.9% increase in full-year revenue and announced Vladimir A. Makatsaria as the new CEO, effective March 1, 2024.

Summary

• LivaNova's fourth-quarter revenue reached $310.1 million, a 12.8% increase on a reported basis and 11.9% on a constant-currency basis compared to the previous year.
• Full-year 2023 revenue was $1.15 billion, showing a 12.9% increase on a reported basis and 13.3% on a constant-currency basis.
• The company's U.S. GAAP diluted earnings per share for the fourth quarter was $0.30, while adjusted diluted earnings per share was $0.87.
• For the full year, U.S. GAAP diluted earnings per share was $0.32, and adjusted diluted earnings per share was $2.80.
• LivaNova is winding down its Advanced Circulatory Support segment, expected to be substantially complete by the end of 2024.
• Vladimir A. Makatsaria will become the new CEO on March 1, 2024, succeeding Bill Kozy, who will remain Board Chair.
• The company expects 2024 revenue to grow between 4% and 5% on a constant-currency basis, or 6% to 7% excluding the impact of the ACS segment wind down.
• Adjusted diluted earnings per share for 2024 are projected to be between $2.95 and $3.05, with an estimated adjusted free cash flow of $95 to $115 million.

Sentiment

Score: 7

Explanation: The document presents a generally positive outlook with strong revenue growth and a new CEO, but there are some concerns about operating losses and the wind down of a business segment. The guidance for 2024 is positive, but the risks mentioned temper the overall sentiment.

Positives

• LivaNova experienced strong revenue growth in both the fourth quarter and full year of 2023.
• The company achieved double-digit revenue growth across all regions.
• There was an improvement in the adjusted operating margin.
• Adjusted diluted earnings per share increased by 17% for the full year.
• The company is refining its business strategy and portfolio.
• The wind down of the Advanced Circulatory Support segment is expected to positively contribute to adjusted operating income in 2024.
• The appointment of a new CEO is expected to bring strong leadership to the company.

Negatives

• The company reported a U.S. GAAP operating loss of $88.0 million for the fourth quarter of 2023.
• The company reported a U.S. GAAP operating loss of $68.5 million for the full year of 2023.
• The Advanced Circulatory Support segment is being wound down, indicating underperformance in that area.
• There was an impairment of long-lived assets of $90 million in the fourth quarter.

Risks

• The company faces risks related to global market volatility and economic conditions.
• There are risks associated with cyber-attacks and disruptions to information technology systems.
• The company is exposed to risks related to supply chain interruptions.
• There are risks related to product recalls, enforcement actions, and product liability claims.
• The company faces risks from pending or future lawsuits and governmental investigations, including the 3T Heater-Cooler and SNIA litigations.
• There are risks associated with environmental laws and regulations.
• The company faces risks related to its indebtedness.
• There are risks related to the effectiveness of internal controls over financial reporting.
• The company faces risks related to fluctuations in quarterly operating results.

Future Outlook

LivaNova expects revenue for full-year 2024 to grow between 4 and 5 percent on a constant-currency basis, or 6 to 7 percent excluding the impact of the ACS segment wind down. Adjusted diluted earnings per share for 2024 are expected to be in the range of $2.95 to $3.05.

Management Comments

• Bill Kozy, Interim Chief Executive Officer and Board Chair of LivaNova, stated that the 2023 performance reflects double-digit revenue growth across all regions, an improvement in adjusted operating margin and a 17% increase in adjusted diluted earnings per share.
• Bill Kozy expressed confidence that LivaNova will build on these results and achieve commitments to serving patients and creating shareholder value under the leadership of Vlad Makatsaria.

Industry Context

The medical technology industry is experiencing growth, and LivaNova's results reflect this trend. The company's focus on core segments like Cardiopulmonary and Neuromodulation aligns with the industry's emphasis on specialized medical devices. The appointment of a new CEO with experience at Johnson & Johnson MedTech suggests a strategic move to enhance market position.

Comparison to Industry Standards

• LivaNova's revenue growth of 12.9% for the full year is strong compared to some of its peers in the medical device industry, although specific comparisons would require a deeper analysis of individual company results.
• Companies like Medtronic and Abbott have also reported growth, but their specific segments and product portfolios differ from LivaNova, making direct comparisons challenging.
• The wind down of the ACS segment is a strategic move that may improve profitability, similar to how other medical device companies have streamlined their portfolios to focus on core competencies.
• LivaNova's adjusted diluted EPS of $2.80 for 2023 is a positive result, but it is important to compare this to the average EPS of companies in the medical technology sector to assess its relative performance.

Management Changes

Legal Proceedings

• The company faces ongoing legal challenges, including the 3T Heater-Cooler and SNIA litigations.

Stakeholder Impact

• Shareholders will likely react positively to the strong revenue growth and new CEO appointment.
• Employees may experience changes due to the wind down of the ACS segment.
• Customers will continue to be served by the core Cardiopulmonary and Neuromodulation segments.
• Suppliers may need to adjust to changes in the company's product portfolio.

Next Steps

• LivaNova will complete the wind down of the Advanced Circulatory Support segment by the end of 2024.
• Vladimir A. Makatsaria will assume the role of CEO on March 1, 2024.
• The company will focus on its core Cardiopulmonary and Neuromodulation segments.
• LivaNova will continue to execute its strategic plan and work towards achieving its 2024 financial guidance.

Key Dates

Keywords

LivaNova, medical technology, cardiopulmonary, neuromodulation, financial results, CEO, revenue growth, earnings per share, constant currency, adjusted operating income